---
title: "Sacituzumab tirumotecan plus pembrolizumab shows activity in PD-L1–negative NSCLC"
id: "nature-reviews-clinical-oncology-1-sacituzumab-tirumotecan-pembrolizumab-has-efficacy-in-pd-l1-negative-nsclc"
canonical_url: "https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-1-sacituzumab-tirumotecan-pembrolizumab-has-efficacy-in-pd-l1-negative-nsclc"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Nature Reviews Clinical Oncology"
source_url: "https://www.nature.com/articles/s41571-026-01232-0"
published_at: "2026-11-06T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Sacituzumab tirumotecan plus pembrolizumab shows activity in PD-L1–negative NSCLC
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-1-sacituzumab-tirumotecan-pembrolizumab-has-efficacy-in-pd-l1-negative-nsclc
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Nature Reviews Clinical Oncology
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41571-026-01232-0)
- **Published At:** 2026-11-06T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The standard first-line for **PD-L1-negative** advanced non-small-cell lung cancer remains pembrolizumab plus chemotherapy, but overall outcomes are suboptimal. - The phase III **OptiTROP-Lung06** trial was conducted in China and randomized 455 patients (1:1) with non-squamous, advanced-stage, PD-L1-negative NSCLC to receive pembrolizumab plus either **sacituzumab tirumotecan** (an anti-TROP2 antibody–drug conjugate) or pemetrexed–platinum chemotherapy. - Investigators reported that **sacituzumab tirumotecan** combined with pembrolizumab demonstrated promising efficacy in this PD-L1-negative population, relative to the standard chemoimmunotherapy comparator. - The trial’s primary end point was **progression-free survival** (PFS). - Results were presented at the ESMO Congress 2026 and simultaneously published in the New England Journal of Medicine. - The Nature Reviews Clinical Oncology piece is a research highlight and does not provide numerical efficacy outcomes, safety data, subgroup analyses, or detailed methodology; those specifics are reported in the NEJM article cited. - Key unanswered questions from the highlighted report include the magnitude of PFS and overall survival benefit, toxicity and tolerability profiles, biomarker correlates beyond PD-L1, and whether findings generalize beyond the study population in China.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41571-026-01232-0#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Reviews Clinical Oncology](https://media.springernature.com/full/nature-cms/uploads/product/nrclinonc/header-6cacb5c22900eb4634682a8eae5b788c.svg) ](https://www.nature.com/nrclinonc) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41571-026-01232-0) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nrclinonc/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nrclinonc/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nrclinonc/news-and-comment) * [ Current issue ](https://www.nature.com/nrclinonc/current-issue) * [ Collections ](https://www.nature.com/nrclinonc/collections) * [Follow us on Facebook ](https://www.facebook.com/NatureReviews) * [Follow us on X ](https://twitter.com/NatRevClinOncol) * [ Subscribe ](https://www.nature.com/nrclinonc/subscribe) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41571) * [ RSS feed ](https://www.nature.com/nrclinonc.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nrclinonc/aims) * [ Journal Information ](https://www.nature.com/nrclinonc/journal-information) * [ Editors ](https://www.nature.com/nrclinonc/editors) * [ Editorial policies ](https://www.nature.com/nrclinonc/editorial-policies) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nrclinonc/reviews-cross-journal-editorial-team) * [ Journal Credits ](https://www.nature.com/nrclinonc/journal-credits) * [ Editorial input and checks ](https://www.nature.com/nrclinonc/editorial-input-and-checks) * [ Editorial Values Statement ](https://www.nature.com/nrclinonc/editorial-values-statement) * [ Journal Metrics ](https://www.nature.com/nrclinonc/journal-impact) * [ Publishing model ](https://www.nature.com/nrclinonc/publishing-model) * [ Conferences ](https://www.nature.com/nrclinonc/conferences) * [ Web Feeds ](https://www.nature.com/nrclinonc/web-feeds) * [ Contact ](https://www.nature.com/nrclinonc/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ For Authors ](https://www.nature.com/nrclinonc/for-authors) * [ For Referees ](https://www.nature.com/nrclinonc/for-referees) * [Submit manuscript ](https://mts-nrclinonc.nature.com/cgi-bin/main.plex) * [ Subscribe ](https://www.nature.com/nrclinonc/subscribe) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41571) * [ RSS feed ](https://www.nature.com/nrclinonc.rss) 1. [nature](https://www.nature.com/) 2. [nature reviews clinical oncology](https://www.nature.com/nrclinonc) 3. [research highlights](https://www.nature.com/nrclinonc/articles?type=research-highlight) 4. article * Research Highlight * Published: 06 November 2026 Lung cancer # Sacituzumab tirumotecan–pembrolizumab has efficacy in PD-L1-negative NSCLC * [Diana Romero](https://www.nature.com/articles/s41571-026-01232-0#auth-Diana-Romero-Aff1)[1](https://www.nature.com/articles/s41571-026-01232-0#Aff1) [_Nature Reviews Clinical Oncology_](https://www.nature.com/nrclinonc) (2026) [Cite this article](https://www.nature.com/articles/s41571-026-01232-0#citeas) Save article [ View saved research ](https://www.nature.com/saved-research) Pembrolizumab plus chemotherapy is the standard-of-care first-line therapy for PD-L1-negative advanced-stage non-small-cell lung cancer (NSCLC), although patient outcomes remain poor. Now, results from the phase III OptiTROP-Lung06 trial, presented at the ESMO Congress 2026 and simultaneously published in the _New England Journal of Medicine_ , demonstrate that the TROP2-directed antibody–drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) has promising efficacy in PD-L1-negative non-squamous advanced-stage NSCLC. In this trial, conducted in China, 455 patients were randomly allocated (1:1) to receive pembrolizumab plus either sac-TMT or pemetrexed–platinum-based chemotherapy (chemoimmunotherapy). Progression-free survival (PFS) was the primary end point. This is a preview of subscription content, [access via your institution](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01232-0) ## Access options [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01232-0) Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 32.70 € / 30 days cancel any time [Learn more](https://shop.nature.com/products/plus/?region=ROW) Subscribe to this journal Receive 12 print issues and online access 176.64 € per year only 14.72 € per issue [Learn more](https://www.nature.com/nrclinonc/subscribe) Buy this article * Purchase on SpringerLink * Instant access to the full article PDF. 39,95 € Prices may be subject to local taxes which are calculated during checkout ### Additional access options: * [Log in](https://idp.nature.com/auth/personal/springernature?client_id=grover&redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01232-0) * [Learn about institutional subscriptions](https://www.springernature.com/gp/librarians/licensing/license-options) * [Read our FAQs](https://support.nature.com/en/support/home) * [Contact customer support](https://www.springernature.com/gp/contact) ### Explore related subjects Discover the latest articles and news in related subjects. * [Cancer immunotherapy](https://www.nature.com/subjects/cancer-immunotherapy) * [Lung cancer](https://www.nature.com/subjects/lung-cancer) * [Targeted therapies](https://www.nature.com/subjects/targeted-therapies) ## References ### Original article * Zhou, F. et al. Sacituzumab tirumotecan plus pembrolizumab in PD-L1-negative advanced NSCLC. _N. Engl. J. Med._ (2026) [Article](https://doi.org/10.1056%2FNEJMoa2611280) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=42981569) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Sacituzumab%20tirumotecan%20plus%20pembrolizumab%20in%20PD-L1-negative%20advanced%20NSCLC&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2611280&publication_year=2026&author=Zhou%2CF) [Download references](https://citation-needed.springer.com/v2/references/10.1038/s41571-026-01232-0?format=refman&flavour=references) ## Author information ### Authors and Affiliations 1. Nature Reviews Clinical Oncology Diana Romero Authors 1. Diana Romero [View author publications](https://www.nature.com/search?author=Diana%20Romero) Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Diana%20Romero)[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Diana%20Romero%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en) ### Corresponding author Correspondence to Diana Romero. ## Rights and permissions [Reprints and permissions](https://s100.copyright.com/AppDispatchServlet?title=Sacituzumab%20tirumotecan%E2%80%93pembrolizumab%20has%20efficacy%20in%20PD-L1-negative%20NSCLC&author=Diana%20Romero&contentID=10.1038%2Fs41571-026-01232-0&copyright=Springer%20Nature%20Limited&publication=1759-4774&publicationDate=2026-11-06&publisherName=SpringerNature&orderBeanReset=true) ## About this article [![Check for updates. Verify currency and authenticity via CrossMark](https://www.nature.com/articles/s41571-026-01232-0)](https://crossmark.crossref.org/dialog/?doi=10.1038/s41571-026-01232-0) ### Cite this article Romero, D. Sacituzumab tirumotecan–pembrolizumab has efficacy in PD-L1-negative NSCLC. _Nat Rev Clin Oncol_ (2026). https://doi.org/10.1038/s41571-026-01232-0 [Download citation](https://citation-needed.springer.com/v2/references/10.1038/s41571-026-01232-0?format=refman&flavour=citation) * Published: 06 November 2026 * Version of record: 06 November 2026 * DOI: https://doi.org/10.1038/s41571-026-01232-0 ### Share this article Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy shareable link to clipboard Provided by the Springer Nature SharedIt content-sharing initiative [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01232-0) [ Buy or subscribe ](https://www.nature.com/articles/s41571-026-01232-0#access-options) * Sections * References * [References](https://www.nature.com/articles/s41571-026-01232-0#Bib1) * [Author information](https://www.nature.com/articles/s41571-026-01232-0#author-information) * [Rights and permissions](https://www.nature.com/articles/s41571-026-01232-0#rightslink) * [About this article](https://www.nature.com/articles/s41571-026-01232-0#article-info) Advertisement 1. Zhou, F. et al. Sacituzumab tirumotecan plus pembrolizumab in PD-L1-negative advanced NSCLC. _N. Engl. J. Med._ (2026) [Article](https://doi.org/10.1056%2FNEJMoa2611280) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=42981569) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Sacituzumab%20tirumotecan%20plus%20pembrolizumab%20in%20PD-L1-negative%20advanced%20NSCLC&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2611280&publication_year=2026&author=Zhou%2CF) Nature Reviews Clinical Oncology (_Nat Rev Clin Oncol_) ISSN 1759-4782 (online) ISSN 1759-4774 (print) ## nature.com footer links ### About Nature Portfolio * [About us](https://www.nature.com/npg_/company_info/index.html) * [Press releases](https://www.nature.com/npg_/press_room/press_releases.html) * [Press office](https://press.nature.com/) * [Contact us](https://support.nature.com/support/home) ### Discover content * [Journals A-Z](https://www.nature.com/siteindex) * [Articles by subject](https://www.nature.com/subjects) * [protocols.io](https://www.protocols.io/) * [Nature Index](https://www.natureindex.com/) ### Publishing policies * [Nature portfolio policies](https://www.nature.com/authors/editorial_policies) * [Open access](https://www.nature.com/nature-portfolio/for-authors/openaccess) ### Author & Researcher services * [Reprints & permissions](https://www.nature.com/reprints) * [Research data](https://www.springernature.com/gp/authors/research-data) * [Language editing](https://authorservices.springernature.com/language-editing/) * [Scientific editing](https://authorservices.springernature.com/scientific-editing/) * [Nature Masterclasses](https://masterclasses.nature.com/) * [Research Solutions](https://solutions.springernature.com/) ### Libraries & institutions * [Librarian service & tools](https://www.springernature.com/gp/librarians/tools-services) * [Librarian portal](https://www.springernature.com/gp/librarians/manage-your-account/librarianportal) * [Open research](https://www.nature.com/openresearch/about-open-access/information-for-institutions) * [Recommend to library](https://www.springernature.com/gp/librarians/recommend-to-your-library) ### Advertising & partnerships * [Advertising](https://partnerships.nature.com/product/digital-advertising/) * [Partnerships & Services](https://partnerships.nature.com/) * [Media kits](https://partnerships.nature.com/media-kits/) * [Branded content](https://partnerships.nature.com/product/branded-content-native-advertising/) ### Professional development * [Nature Awards](https://www.nature.com/immersive/natureawards/index.html) * [Nature Careers](https://www.nature.com/naturecareers/) * [Nature Conferences](https://conferences.nature.com) ### Regional websites * [Nature Africa](https://www.nature.com/natafrica) * [Nature China](http://www.naturechina.com) * [Nature India](https://www.nature.com/nindia) * [Nature Japan](https://www.natureasia.com/ja-jp) * [Nature Middle East](https://www.nature.com/nmiddleeast) * [Privacy Policy](https://www.nature.com/info/privacy) * [Use of cookies](https://www.nature.com/info/cookies) * Your privacy choices/Manage cookies * [Legal notice](https://www.nature.com/info/legal-notice) * [Accessibility statement](https://www.nature.com/info/accessibility-statement) * [Terms & Conditions](https://www.nature.com/info/terms-and-conditions) * [Your US state privacy rights](https://www.springernature.com/ccpa) [ ![Springer Nature](https://www.nature.com/oscar-static/images/logos/sn-logo-white-c8f7a9c061.svg) ](https://www.springernature.com/) © 2026 Springer Nature Limited Close banner Close ![Nature Briefing: Cancer](https://www.nature.com/static/images/logos/nature-briefing-logo-cancer-white-bc2338cade.svg) Sign up for the _Nature Briefing: Cancer_ newsletter — what matters in cancer research, free to your inbox weekly. Email address Sign up I agree my information will be processed in accordance with the _Nature_ and Springer Nature Limited [Privacy Policy](https://www.nature.com/info/privacy). Close banner Close Get what matters in cancer research, free to your inbox weekly. [Sign up for Nature Briefing: Cancer ](https://www.nature.com/briefing/cancer/?brieferEntryPoint=CancerBriefingBanner) *[DOI]: Digital Object Identifier *[ISSN]: International Standard Serial Number
## Related Clinical Research

- [Reanalysis of isotope-resolved metabolomics in patient-derived lung cancer tissue: treatment- and](https://medichelpline.com/clinical-feed/medrxiv-1-treatment-and-tissue-context-specific-isotope-labeling-patterns-in-patient.md)
- [Perioperative ivonescimab ± chemotherapy Yields High MPR in Resectable NSCLC (Phase 2)](https://medichelpline.com/clinical-feed/nature-1-perioperative-ivonescimab-with-or-without-chemotherapy-in-resectable-non-small.md)
- [Phase III data: First-line regimens for advanced NSCLC with EGFR exon 20 insertions and PD-L1+ dis](https://medichelpline.com/clinical-feed/pubmed-42755291.md) (DOI: 10.1158/2159-8290.CD-NW2026-0090)
- [Neoadjuvant durvalumab plus chemotherapy in resectable NSCLC: results from the phase 2 MDT-BRIDGE](https://medichelpline.com/clinical-feed/nature-0-neoadjuvant-durvalumab-plus-chemotherapy-in-resectable-or-borderline-resectable.md)
- [53L10 T‑cell engager tribody for immunotherapy of multiple solid tumors — Frontiers in Immunology](https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-53l10-t-cell-engager-tribody-for-immunotherapy-of-multiple-solid-tumors.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.